Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 8/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.37 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12805526 | 1.00 | P2RY2 (0.44) | P2RY2P2RY4LMNATHRBSMN1; SMN2 | |
| SCHEMBL21418879 | 1.00 | P2RY2 (0.44) | P2RY2P2RY4LMNATHRBSMN1; SMN2 | |
| SCHEMBL16575898 | 1.00 | P2RY2 (0.44) | P2RY2P2RY4LMNATHRBSMN1; SMN2 | |
| SCHEMBL12966484 | 1.00 | P2RY2 (0.44) | P2RY2P2RY4LMNATHRBSMN1; SMN2 | |
| SCHEMBL21418884 | 1.00 | P2RY2 (0.44) | P2RY2P2RY4LMNATHRBSMN1; SMN2 | |
| SCHEMBL21418922 | 0.90 | P2RY2 (0.38) | P2RY2P2RY4LMNATHRBSMN1; SMN2 | |
| SCHEMBL16575900 | 0.90 | P2RY2 (0.38) | P2RY2P2RY4LMNATHRBSMN1; SMN2 | |
| SCHEMBL21418880 | 0.90 | P2RY2 (0.38) | P2RY2P2RY4LMNATHRBSMN1; SMN2 | |
| SCHEMBL19534548 | 0.88 | P2RY2 (0.52) | P2RY2P2RY4LMNATHRBSMN1; SMN2 | |
| SCHEMBL19534469 | 0.88 | P2RY2 (0.52) | P2RY2P2RY4LMNATHRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | P2RY2 316/4885P2RY4 230/4885LMNA 2780/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | P2RY2 89/4885P2RY4 66/4885LMNA 1285/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | P2RY2 452/4885P2RY4 288/4885LMNA 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.